Latest News

North Sea Therapeutics raises US$40m in Series B

Steatohepatitis © Nephron/commons.wikimedia.org/w/index.php?curid=7747223


by tg

NorthSea Therapeutics BV has raised US$40m to provide proof-of-concept of its NASH drug icosabutate.

Besides the completion of the ongoing Phase 2b ICONA study on icosabutate in safety and efficacy in NASH (Non-alcoholic Steatohepatitis), North Sea Therapeutics announced to push the development of two additional SEFA (Structural Engineered Fatty Acids) programmes into clinical development.

While new US investor venBio Partners led the Series B financing, and were joined by Sofinnova Investments, existing investors, Novo Seeds, Forbion, New Science Ventures (NSV) and BioGeneration Ventures (BGV) also participated in the round.

Icosabutate is a structurally enhanced omega-3 fatty acid molecule, which was originally tested to lower triglyceride levels but also showed a reduction in hepatic oxidative stress, according to Naarden-based North Sea Therapeutics.

EuropaBio lobbies for better Orphan Drug rules

The Orphan Drug Regulation adopted in 2000 should be improved to incentivise even ultra-rare conditions with high unmet medical need, according to...

Swiss Biotech Day shows great biopharma ambitions

The Swiss biotech industry is not letting the COVID 19 pandemic slow it down - this was shown at the first live Swiss Biotech Day since the beginning...

Call for pull incentives to get started

With around 30 international experts in the line-up, the virtual conference discussed the current state of the fight against antimicrobial resistance...

Sanofi snaps up mRNA partner for US$3.2bn

Sanofi got ahead of the rumours on Tuesday, announcing it had agreed to acquire US biotech Translate Bio for US$38 per share. Translate Bio brings...

Bayer takes over Vividion

The acquisition strengthens Bayer's oncology and immunology pipeline and secures a revolutionary screening technology for small molecule drugs that...

Novalis Biotech closes biotech fund at €25m

According to the Belgium-headquartered venture capital specialist, the  investor base includes institutional investors, such as Participatie...

Bio-Me raises NOK10m

Both, existing and new investors participated in the financing round, with new investors contributing the majority of the capital. The company said...